keynote-427 cohort b: first-line pembrolizumab monotherapy for advanced non-clear cell renal cel...
Published 5 years ago • 86 plays • Length 5:04Download video MP4
Download video MP3
Similar videos
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
2:25
dr. tykodi on the keynote-427 trial with pembrolizumab in rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
4:10
non-clear cell kidney cancer trial updates: calypso and keynote-427
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
4:20
trial updates in mrcc from asco: keynote-427, resort, e2810 & immotion151
-
1:16
dr. tykodi on the clinical implications of the keynote-427 trial in advanced rcc
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
9:05
drs. rini, wallis on a 5-year analysis of keynote-426 for advanced clear cell rcc
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
5:29
first- and second-line treatments for locally advanced renal cell carcinoma
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
11:18
first-line icis in advanced non-clear cell rcc
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
5:29
drs. lee, mckay on keynote-b61 for non-clear cell rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
7:29
emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma